Urinary metabolic profile of 19-norsteroids in humans: Glucuronide and sulphate conjugates after oral administration of 19-nor-4-androstenediol

Rapid Communications in Mass Spectrometry

Volumn 22, Issue 19, 2008, Pages 3035-3042

  Torrado, Susana ^a,b   Roig, Meritxell ^a,c   Farré, Magi ^a,d   Segura, Jordi ^a,c   Ventura, Rosa ^a,c  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; BODY FLUIDS; GAS CHROMATOGRAPHY; GLUCOSE; METABOLISM; SULFUR COMPOUNDS;

ANALYTICAL PROCEDURE; GLUCURONIC ACIDS; GLUCURONIDE CONJUGATES; GLUCURONIDES; METABOLIC PROFILES; NANDROLONE; NUTRITIONAL SUPPLEMENTS; ORAL ADMINISTRATION; SULFATE CONJUGATES; THRESHOLD CONCENTRATIONS;

METABOLITES;

GLUCURONIDE; NANDROLONE; SULFATE;

ADULT; ARTICLE; DOPING; EVALUATION; HUMAN; MALE; MASS FRAGMENTOGRAPHY; METHODOLOGY; ORAL DRUG ADMINISTRATION; SUBSTANCE ABUSE; URINALYSIS; URINE;

ADMINISTRATION, ORAL; ADULT; DOPING IN SPORTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCURONIDES; HUMANS; MALE; NANDROLONE; SUBSTANCE ABUSE DETECTION; SULFATES; URINALYSIS;

EID: 56149107257     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.3689     Document Type: Article

References (47)

1. http://www.wada-ama.org/rtecontent/document/2007-List-En.pdf (access date: 11-12-06).
2. http://www.wada-ama.org/rtecontent/document/LABSTATS-2005.pdf (access date: 11-12-06).
3. Schänzer W. Clin. Chem. 1996; 42: 1001.
4. WADA. TD2004MRPL, Minimum required performance limits for detection of prohibited substances. WADA Technical Document, 2004; 1-2.
5. Robinson N, Taroni F, Saugy M, Ayotte C, Mangin P, Dvorak J. Forensic Sci. Int. 2001; 122: 130.
6. Le Bizec B, Bryand F, Gaudin I, Monteau F, Poulain F, Andre F. J. Anal. Toxicol. 2002; 26: 43.
7. Le Bizec B, Monteau F, Gaudin I, Andre F. J. Chromatogr. B 1999; 723: 157.
8. Gambelunghe C, Sommavilla M, Rossi R. Biomed. Chromatogr. 2002; 16: 508.
9. Dehennin L, Bonnaire Y, Plou Ph. J. Chromatogr. B 1999; 721: 301.
10. Reznik Y, Dehennin L, Coffin C, Mahoudeau J, Leymarie P. J. Clin. Endocrinol. Metab. 2001; 86: 146.
11. Kohler RMN, Lambert MI. Br. J. Sports Med. 2002; 36: 325.
12. Grosse J, Anielski P, Hemmersbach P, Lund H, Mueller RK, Rautenberg C, Thieme D. Steroids 2005; 70: 499.
13. De Wasch K, Le Bizec B, De Brabander H, Andre F, Impens S. Rapid Commun. Mass Spectrom. 2001; 15: 1442.
14. Le Bizec B, Gaudin I, Monteau F, Andre F, Impens S, De Wasch K, De Brabander H. Rapid Commun. Mass Spectrom. 2000; 14: 1058.
15. Geyer H, Mareck-Engelke U, Reinhart U, Thevis M. Deutsche Zeitschrift für sportmedizin 2000; 51: 378.
16. Delbeke FT, Van Eenoo P, Van Thuyne W, Desmet N. J. Steroid Biochem. Mol. Biol. 2003; 83: 245.
17. Tseng YL, Kuo F-H, Sun K-H. J. Anal. Toxicol. 2005; 29: 124.
18. Catlin DH, Leder BZ, Ahrens B, Starcevic B, Hatton CK, Green GA, Finkelstein JS. J. Am. Med. Assn. 2000; 284: 2618.
19. van der Merwe PJ, Grobbelaar E. S. African Med. J. 2005; 95: 510.
20. Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W. Int. J. Sports Med. 2004; 25: 124.
21. Parr MK, Geyer H, Reinhart U, Schänzer W. Food Addit. Contamin. 2004; 21: 632.
22. De Cock KJS, Delbeke FT, Van Eenoo P, Desmet N, Roels K, De Backer P. J. Pharm. Biomed. Anal. 2001; 25: 843.
23. Kamber M, Baume N, Saugy M, Rivier L. Int. J. Sport Nutr. Exercise Metab. 2001; 11: 258.
24. Baume N, Mahler N, Kamber M, Mangin P, Saugy M. Scan. J. Med. Sci. Sports 2005; 16: 41.
25. Van Thuyne W, Delbeke FT. Biomed. Chromatogr. 2004; 18: 155.
26. US Dietary Supplement and Health Education Act of 1994. Public Law 103-417. 103rd Congress.
27. US Anabolic Steroid Control Act of 2004. S 2195. 108th Congress.
28. Colker CM, Antonio J, Kalman D. J. Strength Conditioning Res. 2001; 15: 144.
29. Le Bizec B, Bryand F, Gaudin I, Monteau F, Poulain F, Andre F. Steroids 2002; 67: 105.
30. Thieme D, Anielski P, Grosse J, Sachs H, Mueller RK. Anal. Chim. Acta 2003; 483: 299.
31. Pepin G, Vayssette F, Gallard Y. Annales Pharmaceutiques Francaises 2001; 59: 345.
32. Kintz P, Cirimele V, Ludes B. Acta Clinica Belgica Supplementum 1999; 1: 68.
33. Uralets VP, Gillette PA. J. Anal. Toxicol. 1999; 23: 357.
34. Uralets VP, Gillette PA. J. Anal. Toxicol. 2000; 24: 188.
35. Tseng YL, Sunb C-Y, Kuob F-H. Steroids 2006; 71: 817.
36. Roig M, Segura J, Ventura R. Anal. Chim. Acta 2007; 586: 184.
37. Ventura R, Roig M, Perez B, Lopez S, Medina M, Bosch J, Segura J. Rapid Commun. Mass Spectrom. 2008; 22: 1863.
38. Torrado S, Segura J, Farré M, Ventura R. Steroids 2008; 73: 751.
39. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Wiswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. J. Pharm. Sci. 1992; 81: 309.
40. Hartmann C, Massart DL, McDowall RD. J. Pharm. Biomed. Anal. 1994; 12: 1337.
41. Center for Drug Evaluation and Research. Guidance for Industry; Bioanalytical Method Validation, US Food and Drug Administration: Rockville, 2001.
42. Dehennin L, Lafarge P, Dailly Ph, Bailloux D, Lafarge J-P. J. Chromatogr. B 1996; 687: 85.
43. Borts DJ, Bowers LD. J. Mass Spectrom. 2000; 35: 50.
44. Kuuranne T, Kurkela M, Thevis M, Schänzer W, Finel M, Kostiainen R. Drug Metab. Dispos. 2003; 31: 1117.
45. Van Eenoo P, Delbeke FT. J. Steroid Biochem. Mol. Biol. 2006; 101: 161.
46. Kicman AT, Gower DB. Ann. Clin. Biochem. 2003; 40: 321.
47. WADA. TD2004NA, Reporting norandrosterone findings, WADA Technical Document 2004; 1-6.